SCHEMBL6523544

SCHEMBL6523544

Clc1cccc(Oc2ccc3c(Cl)nc4ncccc4c3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.46
SCN5A Q14524 1/20 0.42
SCN9A Q15858 1/20 0.42
ABCG2 Q9UNQ0 2/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2C9 P11712 1/20 0.40
TTBK1 Q5TCY1 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PPP1CA P62136 1/20 0.37
ABL1 P00519 1/20 0.37
TTBK2 Q6IQ55 1/20 0.36
MAP4K4 O95819 1/20 0.36
EGFR P00533 1/20 0.36
LCK P06239 1/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454517 0.89 HCAR2 (0.43) HCAR2SCN9ACYP1A2CYP2C9MEN1
SCHEMBL6520629 0.87 HCAR2 (0.45) HCAR2ABCG2ABL1MAP4K4MAPT
SCHEMBL3453868 0.87 ABCG2 (0.44) ABCG2MAPTSMN1; SMN2IDO1
SCHEMBL3453991 0.84 RAB9A (0.41) HCAR2ABCG2MAPTGAALMNA
SCHEMBL6524942 0.81 IDO1 (0.45) HCAR2ABCG2CYP1A2CYP2C19MEN1
SCHEMBL6517522 0.81 CYP19A1 (0.44) HCAR2SCN5ASCN9AABCG2SMN1; SMN2
SCHEMBL3454218 0.81 BCHE (0.41) MEN1KMT2AMAPTLMNAHPGD
SCHEMBL6525007 0.79 KDM4E (0.41) HCAR2EGFR
SCHEMBL6523495 0.78 MAT2A (0.41) HCAR2SCN5ASCN9AABCG2IDO1
SCHEMBL6527179 0.75 IDO1 (0.45) HCAR2ABCG2MAPTLMNAIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 HCAR2 4241/4885SCN5A 3114/4885SCN9A 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.